Used topically to treat bacterial skin infections such as impetigo and infected wounds, ozenoxacin is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). As a non-fluorinated quinolone, it offers an alternative for patients who may not tolerate other antibiotics. Its mechanism involves inhibiting bacterial DNA gyrase and topoisomerase IV, which prevents replication and transcription, leading to bacterial cell death. Due to its localized action and low systemic absorption, it minimizes the risk of widespread side effects.